Organon Announces US FDA Approval of Supplemental New Drug Application Extending Duration of Use of Nexplanon (etonogestrel implant) for Up to Five Years

Jan 28, 2026 - 14:00
 0  0
JERSEY CITY, N.J.--(BUSINESS WIRE) January 16, 2026 -- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the US Food and Drug Administration...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0